The Company has two reportable operating segments: Oncology Systems and Proton Solutions. The Company's Interventional Solutions business is reflected in the "Other" category because it does not meet the criteria for a reportable operating segment. The operating segments were determined based on how the Company’s Chief Executive Officer, its Chief Operating Decision Maker (“CODM”), views and evaluates the Company’s operations. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on operating earnings.

The Oncology Systems segment designs, manufactures, sells and services hardware and software products for treating cancer with conventional radiation therapy, and advanced treatments such as fixed field intensity-modulated radiation therapy (“IMRT”), image-guided radiation therapy (“IGRT”), volumetric modulated arc therapy ("VMAT"), stereotactic radiosurgery (“SRS”), stereotactic body radiotherapy (“SBRT”) and brachytherapy as well as associated quality assurance equipment.

The Oncology Systems’ hardware products include linear accelerators, brachytherapy afterloaders, treatment accessories, artificial intelligence-powered adaptive delivery systems and quality assurance software. The Oncology Systems’ software solutions include treatment planning, informatics, clinical knowledge exchange, patient care management, practice management and decision support for comprehensive cancer clinics, radiotherapy centers and medical oncology practices.

Oncology Systems’ products enable radiation oncology departments in hospitals and clinics to perform conventional radiotherapy treatments and offer advanced treatments such as IMRT, IGRT, VMAT, SRS and SBRT, and treat patients using brachytherapy techniques, which involve the introduction or temporary insertion of radioactive sources. The Oncology Systems' products are also used by surgeons and radiation oncologists to perform stereotactic radiosurgery and by medical oncology departments to manage patient treatments. Oncology Systems’ customers worldwide include university research and community hospitals, private and governmental institutions, healthcare agencies, physicians’ offices, medical oncology practices, radiotherapy centers and cancer care clinics.

The Oncology Systems segment offers services ranging from hardware phone support, break/fix repair of linear accelerators, obsolescence protection of hardware, software support, software upgrades, hosting as a service, as well as clinical consulting services.

The Oncology Systems segment also provides clinical practice services that assist within the clinical workflow. These services focus on decision support and/or cancer care knowledge augmentation aimed at facilitating improved accessibility and affordability to care while maintaining a fundamental level of clinical quality. Further, the Company operates ten multi-disciplinary cancer centers and one specialty hospital in India and one multi-disciplinary cancer center in Sri Lanka.

The Proton Solutions segment develops, designs, manufactures, sells and services products and systems for delivering proton therapy, another form of external beam radiotherapy using proton beams, for the treatment of cancer.

The Other category primarily includes the Interventional Solutions business, which offers products for interventional oncology procedures and treatments, including cryoablation, microwave ablation and embolization. Interventional Solutions also provides software and remote services for post treatment dose calculation for Yttrium-90 microspheres used in selective internal radiation therapy. The Other category also includes assets related to the use of radiation in the heart and other forms of radiosurgery for cardiovascular disease.

The following information is provided for the purpose of achieving an understanding of operations but may not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company’s operations to similar operations of other companies may not be meaningful.

The Company allocates corporate costs to its operating segments based on the relative revenues of Oncology Systems, Proton Solutions and Interventional Solutions. The Company allocates these costs, excluding certain corporate related costs, transactions or adjustments that the Company's CODM considers to be non-operational, such as restructuring and impairment charges, significant litigation charges or benefits and legal costs, and acquisition-related expenses and in process research and development. Although the Company excludes these amounts from segment operating earnings, they are included in the condensed consolidated operating earnings and included in the reconciliation below.


	Three Months Ended
(In millions)	January 3, 2020		December 28, 2018
Revenues
Oncology Systems	$	782.4	$	702.5
Proton Solutions	27.6		38.5
Total reportable segments	810.0		741.0
Other	18.9		—
Total Company	$	828.9	$	741.0
Earnings from continuing operations before taxes
Oncology Systems	$	136.4	$	124.1
Proton Solutions	(14.3)		(8.8)
Total reportable segments	122.1		115.3
Other	2.8		—
Unallocated corporate	(14.9)		(3.6)
Operating earnings	110.0		111.7
Interest income (expense), net	(1.7)		2.7
Other income, net	4.4		23.0
Total Company	$	112.7	$	137.4

The Company disaggregates its revenues from contracts by major product categories, geographic region, and by timing of revenue recognition for each of its reportable operating segments, as the Company believes this best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. See details in the tables below.


	Three Months Ended
Total Revenues by Product Type	January 3,		December 28,
(In millions)	2020		2018
Hardware
Oncology Systems	$	320.0	$	313.6
Proton Solutions	20.1		33.6
Other	18.9		—
Total Hardware	359.0		347.2
Software ⁽¹⁾
Oncology Systems	148.8		131.2
Proton Solutions	—		—
Total Software	148.8		131.2
Service
Oncology Systems	313.6		257.7
Proton Solutions	7.5		4.9
Total Service	321.1		262.6
Total Revenues	$	828.9	$	741.0

⁽¹⁾Includes software support agreements that are recorded in revenues from service, and software licenses that are recorded in revenues from product in the Condensed Consolidated Statements of Earnings.


	Three Months Ended
Total Revenues by Geographical Region	January 3,		December 28,
(In millions)	2020		2018
Americas
Oncology Systems	$	378.9	$	330.8
Proton Solutions	16.9		19.6
Other	6.4		—
Total Americas	402.2		350.4
EMEA
Oncology Systems	259.8		234.5
Proton Solutions	10.3		16.5
Other	2.8		—
Total EMEA	272.9		251.0
APAC
Oncology Systems	143.7		137.2
Proton Solutions	0.4		2.4
Other	9.7		—
Total APAC	153.8		139.6
Total Revenues	$	828.9	$	741.0
North America ⁽¹⁾
Oncology Systems	$	355.2	$	309.1
Proton Solutions	16.9		19.6
Other	6.4		—
Total North America	378.5		328.7
International
Oncology Systems	427.2		393.4
Proton Solutions	10.7		18.9
Other	12.5		—
Total International	450.4		412.3
Total Revenues	$	828.9	$	741.0


	Three Months Ended
Timing of revenue recognition	January 3,		December 28,
(In millions)	2020		2018
Products transferred at a point in time
Oncology Systems	$	382.0	$	366.6

Other	18.9		—
Total products transferred at a point in time	400.9		366.6
Products and services transferred over time
Oncology Systems	400.4		335.9
Proton Solutions	27.6		38.5

Total products and services transferred over time	428.0		374.4
Total Revenues	$	828.9	$	741.0